Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 02
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Open market or private sale
|
Indirect |
40,000
-35.26%
|
$10,000,000
$250.01 P/Share
|
|
Aug 02
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Open market or private sale
|
Direct |
409
-9.24%
|
$101,841
$249.57 P/Share
|
|
Jul 30
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Open market or private sale
|
Direct |
2,900
-39.58%
|
$722,100
$249.43 P/Share
|
|
Jul 29
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Open market or private sale
|
Direct |
200
-2.66%
|
$49,800
$249.36 P/Share
|
|
Jul 28
2021
|
Bill B Rutherford CFO and EVP |
SELL
Bona fide gift
|
Direct |
200
-0.4%
|
-
|
|
Jul 28
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Indirect |
23,268
+50.0%
|
-
|
|
Jul 28
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Direct |
20,000
-90.56%
|
-
|
|
Jul 28
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Direct |
20,000
+26.21%
|
-
|
|
Jul 28
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Indirect |
23,268
-65.21%
|
-
|
|
Jul 27
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,782
-38.85%
|
$1,181,154
$247.69 P/Share
|
|
Jul 27
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,800
+31.76%
|
$510,400
$58.47 P/Share
|
|
Jul 27
2021
|
Charles J Hall Group President |
SELL
Open market or private sale
|
Direct |
3,000
-1.45%
|
$747,000
$249.94 P/Share
|
|
Jul 27
2021
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
7,466
-36.7%
|
$1,866,500
$250.0 P/Share
|
|
Jul 26
2021
|
Charles J Hall Group President |
SELL
Bona fide gift
|
Direct |
3,270
-1.56%
|
-
|
|
Jul 22
2021
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
886
-9.08%
|
$217,956
$246.9 P/Share
|
|
Jul 21
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
1,000
-5.92%
|
$252,000
$252.0 P/Share
|
|
Jul 21
2021
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,614
-32.09%
|
$2,393,886
$249.25 P/Share
|
|
Jul 21
2021
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,080
+36.31%
|
$1,178,520
$69.58 P/Share
|
|
May 13
2021
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
4,919
+9.13%
|
-
|
|
May 13
2021
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Indirect |
4,919
-100.0%
|
-
|
|
May 12
2021
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
9,838
+29.57%
|
-
|
|
May 12
2021
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Direct |
9,838
-75.0%
|
-
|
|
May 11
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Open market or private sale
|
Direct |
3,432
-34.29%
|
$713,856
$208.33 P/Share
|
|
May 06
2021
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
7,672
-37.33%
|
$1,588,104
$207.55 P/Share
|
|
May 05
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
40,626
-44.8%
|
$8,409,582
$207.19 P/Share
|
|
May 04
2021
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,328
-35.54%
|
$2,333,568
$206.34 P/Share
|
|
May 04
2021
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+37.34%
|
$1,292,000
$68.96 P/Share
|
|
May 04
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
19,043
-17.35%
|
$3,903,815
$205.3 P/Share
|
|
May 04
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
4,604
-14.23%
|
$939,216
$204.0 P/Share
|
|
May 03
2021
|
A Bruce Moore Jr Group President - Service Line |
SELL
Open market or private sale
|
Direct |
12,000
-10.49%
|
$2,460,000
$205.32 P/Share
|
|
May 03
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
2,417
-12.51%
|
$493,068
$204.32 P/Share
|
|
May 03
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
21,584
-16.44%
|
$4,424,720
$205.21 P/Share
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Bona fide gift
|
Indirect |
46,890
+39.71%
|
-
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Indirect |
23,445
-100.0%
|
-
|
|
Apr 30
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Bona fide gift
|
Direct |
23,445
-91.83%
|
-
|
|
Apr 30
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,396
-18.61%
|
$1,486,596
$201.06 P/Share
|
|
Apr 30
2021
|
Christopher F. Wyatt SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+13.97%
|
$888,000
$74.69 P/Share
|
|
Apr 30
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,843
-1.38%
|
$374,129
$203.06 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
18,664
-47.82%
|
$3,751,464
$201.53 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,794
-8.86%
|
$762,594
$201.94 P/Share
|
|
Apr 29
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,930
+12.16%
|
$480,330
$81.96 P/Share
|
|
Apr 29
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
72,846
-10.05%
|
$14,642,046
$201.56 P/Share
|
|
Apr 28
2021
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+17.49%
|
-
|
|
Apr 28
2021
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+3.74%
|
-
|
|
Apr 28
2021
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+4.53%
|
-
|
|
Apr 28
2021
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,938
+17.85%
|
-
|
|
Apr 28
2021
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,435
+14.49%
|
-
|
|
Apr 28
2021
|
Charles O Holliday Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+4.65%
|
-
|
|
Apr 28
2021
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,435
+17.48%
|
-
|
|
Apr 28
2021
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
881
+7.0%
|
-
|